Cargando…
Practices of US health insurance companies concerning MS therapies interfere with shared decision-making and harm patients
The US Food and Drug Administration has registered 13 multiple sclerosis (MS) disease-modifying therapies (DMTs). The medications are not interchangeable as they vary in route of administration, efficacy, and safety profile. Selecting the appropriate MS DMT for individual patients requires shared de...
Autores principales: | Bourdette, Dennis N., Hartung, Daniel M., Whitham, Ruth H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828681/ https://www.ncbi.nlm.nih.gov/pubmed/27104069 http://dx.doi.org/10.1212/CPJ.0000000000000208 |
Ejemplares similares
-
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
por: Hartung, Daniel M., et al.
Publicado: (2015) -
Selection of an Insurance Company in Agriculture through Hybrid Multi-Criteria Decision-Making
por: Puška, Adis, et al.
Publicado: (2023) -
Implementation of Shared Decision Making for Lung Cancer Screening Among the Privately Insured Nonelderly
por: Shih, Ya-Chen Tina, et al.
Publicado: (2021) -
Involvement of people with dementia in making decisions about their lives: a qualitative study that appraises shared decision-making concerning daycare
por: Groen-van de Ven, Leontine, et al.
Publicado: (2017) -
Big data for insurance companies
por: Corlosquet-Habart, Marine, et al.
Publicado: (2018)